Jorge E Buendia-Buendia
Overview
Explore the profile of Jorge E Buendia-Buendia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez Tejeda Zanudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia J, et al.
Nat Commun
. 2024 Mar;
15(1):2446.
PMID: 38503755
The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of...
2.
Balch S, Vaz-Luis I, Li T, Tayob N, Jain E, Helvie K, et al.
Breast Cancer Res Treat
. 2021 Jul;
189(2):411-423.
PMID: 34302589
Purpose: There are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival...
3.
Jerby-Arnon L, Neftel C, Shore M, Weisman H, Mathewson N, McBride M, et al.
Nat Med
. 2021 Jan;
27(2):289-300.
PMID: 33495604
Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we studied the cancer-immune interplay in SyS using an...
4.
Mao P, Cohen O, Kowalski K, Kusiel J, Buendia-Buendia J, Cuoco M, et al.
Clin Cancer Res
. 2020 Jul;
26(22):5974-5989.
PMID: 32723837
Purpose: To identify clinically relevant mechanisms of resistance to ER-directed therapies in ER breast cancer. Experimental Design: We conducted a genome-scale functional screen spanning 10,135 genes to investigate genes whose...
5.
Wander S, Cohen O, Gong X, Johnson G, Buendia-Buendia J, Lloyd M, et al.
Cancer Discov
. 2020 May;
10(8):1174-1193.
PMID: 32404308
Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR) breast cancer have not been clearly defined. Whole-exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple...
6.
Danecek P, Nellaker C, McIntyre R, Buendia-Buendia J, Bumpstead S, Ponting C, et al.
Genome Biol
. 2012 Apr;
13(4):26.
PMID: 22524474
Background: Adenosine-to-inosine (A-to-I) editing is a site-selective post-transcriptional alteration of double-stranded RNA by ADAR deaminases that is crucial for homeostasis and development. Recently the Mouse Genomes Project generated genome sequences...